Try the modernized ClinicalTrials.gov beta website. Learn more about the modernization effort.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Role of Hazelnut Consumption in Improving Micronutrient Status in Older Adults

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03485989
Recruitment Status : Completed
First Posted : April 3, 2018
Last Update Posted : August 28, 2019
Sponsor:
Collaborator:
Hazelnut Marketing Board
Information provided by (Responsible Party):
Maret Traber, Oregon State University

Brief Summary:

With advancing age, older adults are susceptible to vitamin and mineral deficiencies for a variety of reasons. Nutrient-dense food sources of vitamin E and other key vitamins and minerals, like hazelnuts, may offer a simple means of improving nutritional status of healthy older adults.

This hypothesis is that individuals eating hazelnuts everyday will result in measurable increases in magnesium and vitamin E levels, two under-consumed micronutrients among older adults. Thus, subjects will consume two ounces (56 g) of hazelnuts each day for sixteen weeks. Investigators will measure vitamin E and magnesium levels along with a general assessment of micronutrient status as primary outcomes. Since nuts are nutrient-rich sources of unsaturated fatty acids but low in carbohydrates, changes in fasting glucose, lipid and lipoprotein profiles, and BMI will also be determined (secondary outcomes).


Condition or disease Intervention/treatment Phase
Nutrition Poor Micronutrient Deficiency Aging Other: Hazelnuts Not Applicable

Detailed Description:

Older adults are at increased risk of various chronic diseases where inadequate levels of vitamins and minerals may play a significant role, including cardiovascular disease, Alzheimer's disease, liver disease, and cancer. Older adults are increasingly more susceptible to vitamin and mineral deficiencies with changes in dietary preferences, changes in socioeconomic status, decreased consumption of a variety of foods, poor absorption in the gut, and an increased demand for many of these micronutrients with advanced age.

Epidemiological studies and recent clinical trials have shown that use of multivitamin/mineral or single nutrient supplements, such as vitamin E, have beneficial effects on disease risk, but many people are hesitant to use dietary supplements due to reports of ineffectiveness or potential negative effects. However, food sources of vitamin E and other key vitamins and minerals continue to show health benefits. As an alternative to mandating consumption of multivitamin and mineral supplements or food fortification, a dietary solution is to increase consumption of nutrient-dense foods, like hazelnuts.

Tree nuts, including hazelnuts, contain a wide variety of vitamins and minerals, and are particularly good source of vitamin E and magnesium, two "shortfall nutrients" that are lacking in the typical American diet. Over 90% of U.S. adults do not meet recommended intake levels of vitamin E, and 60% do not get enough magnesium. Tree nuts are also a good source of protein and fiber and are high in healthful unsaturated fatty acids and phytochemicals such as flavonoids and phytosterols.

Most clinical studies on the benefits of nut consumption have been conducted using almonds and walnuts, with hazelnuts used less frequently. However, the health benefits of consuming hazelnuts have been demonstrated in many clinical trials, including lower blood glucose levels, alterations in blood lipids, and declines in biomarkers of oxidative stress. Although several clinical trials have investigated nutritional impact of hazelnuts in adults, no clinical trials with hazelnuts have focused on examining micronutrient status and potential health benefits only in older (≥55 years) adults.

Determination of body status of many micronutrients can be difficult, especially so the evaluation of vitamin E levels when age is considered as a factor. Although serum α-tocopherol levels are generally higher in adults above the age of 50 compared to younger adults, the increased prevalence of hypercholesterolemia in older adults makes interpretation of circulating α-tocopherol levels difficult. Alternatively, urinary α- and γ-carboxyethyl hydroxychromanol (α- and γ-CEHC) is believed to be a biomarker of α- and γ-tocopherol status that changes with vitamin E intake. In particular, low α-CEHC excretion is considered a reliable marker of poor α-tocopherol status, while an increase in α-CEHC is indicative of adequate α-tocopherol status.

The objective of this study was to determine whether daily hazelnut consumption by healthy older adults for 16 weeks improves biomarkers of micronutrient status, especially vitamin E and magnesium. For a detailed assessment of vitamin E status, plasma α- and γ-tocopherol concentrations were determined together with urinary α- and γ-CEHC levels. In addition, a commercially available lymphocyte proliferation assay was utilized to evaluate the status of several other micronutrients. Since hazelnut consumption is reported to reduce blood lipids and improve glucose homeostasis, these biomarkers were also monitored in our study.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 41 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Basic Science
Official Title: Role of Hazelnut Consumption in Improving Micronutrient Status in Older Adults
Actual Study Start Date : June 22, 2016
Actual Primary Completion Date : September 18, 2017
Actual Study Completion Date : December 29, 2017

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Vitamin E

Arm Intervention/treatment
Experimental: Hazelnuts
Participants given 2 ounces (~57 grams) of dry roasted hazelnuts to consume each day.
Other: Hazelnuts
Dry roasted, individually packaged hazelnuts provided from the Hazelnuts Marketing Board of Oregon




Primary Outcome Measures :
  1. Changes in Plasma Micronutrient Levels [ Time Frame: Between baseline (Visit 2) and 16 weeks (last visit) ]
    Plasma levels of magnesium and vitamin E (alpha and gamma tocopherol) at baseline and 16 weeks after hazelnut intervention will be determined. Vitamin E analyses will be performed as absolute concentrations and concentrations corrected for total plasma lipids.

  2. Changes in Plasma Urine Vitamin E Metabolites [ Time Frame: Between baseline (Visit 2) and 16 weeks (last visit) ]
    Urine concentrations of alpha and gamma carboxyethyl hydroxychroman (metabolites of alpha and gamma tocopherol, respectively) will be determined at baseline and 16 weeks after hazelnut intervention. Urine values will be corrected for creatinine levels.

  3. Changes in Lymphocyte Proliferation Assay [ Time Frame: Between baseline (Visit 2) and 16 weeks (last visit) ]
    Blood samples will be collected and sent to Spectracell Labs, Inc. for a functional micronutrient analysis utilizing their proprietary lymphocyte proliferation assay. Micronutrient levels in these white blood cell samples will be assessed by changes in lymphocyte proliferation in the absence of a given vitamin or mineral, suggesting functional inadequacies that may not correspond to plasma values. Data will be represented as percent difference in cell proliferative capacity in cells growing in a complete media vs. a single-nutrient deprived media.


Secondary Outcome Measures :
  1. Lipid Status [ Time Frame: Between baseline (Visit 2) and 16 weeks (last visit) ]
    Lipid profile will be determined from samples blood sent to a CLIA(Clinical Laboratory Improvement Amendments)-certified laboratory. Changes to fasting lipoprotein and triglyceride status determined before and after hazelnut intervention.

  2. Glucose Homeostasis [ Time Frame: Between baseline (Visit 2) and 16 weeks (last visit) ]
    Glucose and insulin levels will be determined from blood samples to a CLIA-certified laboratory. Changes to fasting glucose levels and insulin levels determined before and after hazelnut intervention.

  3. BMI [ Time Frame: Between baseline (Visit 2) and 16 weeks (last visit) ]
    Height and weight will be measured by stadiometer and scale. Changes to height and weight will be expressed as BMI calculated before and after hazelnut intervention.

  4. Blood Pressure [ Time Frame: Between baseline (Visit 2) and 16 weeks (last visit) ]
    Changes to resting systolic and diastolic blood pressure (mmHg) will be measured by sphygmomanometer before and after hazelnut intervention.

  5. Heart Rate [ Time Frame: Between baseline (Visit 2) and 16 weeks (last visit) ]
    Resting heart rate will be measured manually using the ventral aspect of radial artery.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   55 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Must be generally healthy
  • Women must be post-menopausal (12 months period-free) or surgically sterile.
  • Must be willing to eat two ounces (56 g) of dry roasted hazelnuts each day during the study
  • Must refrain from taking nutritional supplements during the study
  • Must follow a diet that excludes all nuts (other than those supplied), seeds, and other vitamin E-rich foods (see Restricted Foods and Supplements document)
  • Must be willing to complete food frequency questionnaires
  • Must be willing to give blood samples on 3 separate occasions and urine on 2 separate occasions

Exclusion Criteria:

  • Current or past (two years) use of any tobacco (including e-cigarettes) and marijuana products
  • Allergy to any nut including tree nuts and peanuts, or hazelnut pollen
  • History of asthma
  • Vitamin E supplement use during the last three months or regular use of vitamin E-enriched nutritional drinks (e.g. Ensure)
  • Regular nut eaters: individuals that regularly consume > 3.5 ounces (112 g) of almonds, hazelnuts and/or sunflower seeds per week in any form (e.g. nuts, nut butters, nut oil, etc.), and no more than 10 mg alpha-tocopherol (vitamin E) per day from their diet.
  • Bariatric surgery (e.g. gastric bypass, gastric banding, sleeve gastrectomy, etc.), or serious chronic illness including Crohn's disease, celiac disease, diverticulitis, chronic diarrhea, ulcerative colitis, gastritis
  • History of cardiovascular disease including stroke, heart attack, or congestive heart failure
  • Any history of arterial bypass or stent placement.
  • History of emphysema or chronic obstructive pulmonary disease (COPD)
  • Stage II hypertension (either systolic pressure > 159 mm Hg or diastolic pressure 99 mm Hg)
  • History of cancer during the previous 5 years
  • Diabetes (type 1 or type 2) or use of drugs to lower blood sugar or increase insulin production or sensitivity
  • Use of medications to lower cholesterol other than statins
  • Use of medications to decrease fat or cholesterol absorption
  • Unwillingness to refrain from taking dietary supplements (except calcium and vitamin D and vitamin B12), magnesium-containing drugs such as certain antacids, stool softeners and laxatives
  • BMI < 18.5 or > 35
  • Blood chemistry limits; any of the following at screening excludes participation:

    • Fasting blood glucose ≥ 126 mg/dL
    • LDL cholesterol ≥160 mg/dL
    • Triglyceride ≥200 mg/dL
    • High-sensitivity C-reactive protein (hsCRP) > 10 mg/L

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03485989


Locations
Layout table for location information
United States, Oregon
Linus Pauling Science Center
Corvallis, Oregon, United States, 97331
Sponsors and Collaborators
Oregon State University
Hazelnut Marketing Board
Investigators
Layout table for investigator information
Principal Investigator: Maret G Traber, PhD Oregon State University
Publications of Results:
Layout table for additonal information
Responsible Party: Maret Traber, Professor, Oregon State University
ClinicalTrials.gov Identifier: NCT03485989    
Other Study ID Numbers: 6988
First Posted: April 3, 2018    Key Record Dates
Last Update Posted: August 28, 2019
Last Verified: August 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Maret Traber, Oregon State University:
hazelnuts
vitamin E
aging
Additional relevant MeSH terms:
Layout table for MeSH terms
Malnutrition
Nutrition Disorders